BAY 1217389

Catalog No.S8215 Batch:S821502

Print

Technical Data

Formula

C27H24F5N5O3
Molecular Weight 561.50 CAS No. 1554458-53-5
Solubility (25°C)* In vitro DMSO 100 mg/mL (178.09 mM)
Ethanol 5 mg/mL (8.9 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
1.6mg/ml Taking the 1 mL working solution as an example, add 50 μL of 32 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.83mg/ml Taking the 1 mL working solution as an example, add 50 μL of 16.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description BAY 1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1) with IC50 values below 10 nmol/L while showing an excellent selectivity profile.
Targets
Mps1 [1]
(Cell-free assay)
0.63 nM
In vitro In biochemical assays, the IC50 value of BAY 1217389 is 0.63±0.27 nmol/L. It shows high selectivity against other kinases and found to bind to PDGFRβ (<10 nmol/L), Kit (between 10 and 100 nmol/L), CLK1, CLK2, CLK4, JNK1, JNK2, JNK3, LATS1, MAK, MAPKAP2, MERTK, p38β, PDGFRα, PIP5K1C, PRKD1, and RPS6KA5 (between 100 and 1,000 nmol/L). In cellular mechanistic assays, BAY1217389 abrogats nocodazole-induced SAC activity and induced premature exit from mitosis ("mitotic breakthrough"), resulting in multinuclearity and tumor cell death. It is found to inhibit cell proliferation with a median IC50 of 6.7 nmol/L (range 3 to >300 nmol/L)[1].
In vivo In vivo, BAY 1217389 achieves moderate efficacy in monotherapy in tumor xenograft studies. Its blood clearance is found to be low in the tested species. Vss is high and terminal half-lives were long. BAY 1217389 is administered orally to female NMRI mouse (1 mg/kg) and male Wistar rat (0.5 mg/kg). Peak plasma concentrations are observed between 1.5 and 7 hours. Oral bioavailability is high in rat and moderate in mouse[1].

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    Tumor cell lines HeLa-MaTu and HeLa-MaTu-ADR cells

  • Concentrations

    --

  • Incubation Time

    96 h

  • Method

    Cells are seeded into 96-well plates at densities ranging from 1,000 to 5,000 cells per well in the appropriate medium supplemented with 10% FCS. After 24 hours, cells are treated in quadruplicates with serial dilutions of compounds. After further 96 hours, adherent cells are fixed with glutaraldehyde and stained with crystal violet. IC50 values are calculated by means of a 4-parameter fit using the company's own software.
Animal Study:[1]
  • Animal Models

    Male Wistar rats and female CD1 or NMRI nu/nu mice

  • Dosages

    1, 2, 4, or 8 mg/kg (p.o)

  • Administration

    i.v or p.o

Selleck's BAY 1217389 has been cited by 8 publications

CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade [ Nat Commun, 2023, 10.1038/s41467-023-43274-3] PubMed: 37980406
Loss of RanGAP1 drives chromosome instability and rapid tumorigenesis of osteosarcoma [ Dev Cell, 2023, 58(3):192-210.e11] PubMed: 36696903
Chromosomal instability can favor macrophage-mediated immune response and induce a broad, vaccination-like anti-tumor IgG response [ bioRxiv, 2023, 2023.04.02.535275] PubMed: 37066426
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer [ Cancer Cell, 2022, 40(10):1128-1144.e8] PubMed: 36150391
TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma [ BMC Cancer, 2022, 22(1):786] PubMed: 35850753
TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway [ Cell Death Dis, 2021, 12(12):1135] PubMed: 34876569
Single-Chromosomal Gains Can Function as Metastasis Suppressors and Promoters in Colon Cancer. [ Dev Cell, 2020, 52(4):413-428] PubMed: 32097652
Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds [ Nature, 2019, 575(7781):203-209] PubMed: 31666698

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.